CHChikako Hayashi

Chikako Hayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chikako Hayashi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Yoshimoto

    Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU) Tokyo Japan

    1 shared publication
  • Binri Sasaki

    Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU) Tokyo Japan

    1 shared publication
  • Florence M. Bareyre

    Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Haruka Ishii

    Medical Affairs Department, Kyowa Kirin Co., Ltd. , Tokyo 100-0004

    1 shared publication
  • Hee Gyung Kang

    Department of Pediatric Nephrology, Seoul National University Children’s Hospital , Seoul 03080

    1 shared publication
  • Hinako Saito

    Department of Clinical Bioanalysis and Molecular Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo/Tokyo Medical and Dental University (TMDU) Tokyo Japan

    1 shared publication

Latest Publications

  • Open Access

    Effectiveness of burosumab in children with X-linked hypophosphatemia with low rickets severity: SUNFLOWER analysis

    by Hee Gyung Kang, Toshimi Michigami, Noriyuki Namba, Nobuaki Ito, Takuo Kubota, Osamu Miyazaki, Masanori Kanematsu, Chikako Hayashi, Haruka Ishii, Seiji Fukumoto, et al.

    Burosumab provides treatment benefits in children with X-linked hypophosphatemia (XLH). However, children with low rickets severity (Rickets Severity Score [RSS] < 2) were excluded from a previous phase 3, multicenter, active comparator-controlled randomized clinical trial. This descriptive interim analysis of the prospective SUNFLOWER (Study of longitUdinal observatioN For patients with X-Linked hypOphosphatemic rickets/osteomalacia in collaboration With Asian partnERs) cohort study included 69 children with XLH aged ≤13 yr at enrollment. The burosumab and non-burosumab groups included 48 and 65 participants, respectively, with some overlap due to switching. Longitudinal changes in height and biochemical parameters (overall and stratified by disease severity [RSS <2/≥2; alkaline phosphatase </≥ upper limit of normal]) were assessed. In the burosumab all-patients analysis (irrespective of treatment duration or missing follow-up data), height Z-score (initiation: −2.04 ± 1.08; 3 yr: −1.58 ± 1.09), serum phosphate Z-score (initiation: −4.07 ± 1.77; 3 yr: −2.30 ± 1.45), 1,25(OH)2D (initiation: 39.79 ± 22.78 pg/mL; 3 yr: 84.35 ± 28.26 pg/mL), and ratio of tubular maximum phosphate reabsorption to glomerular filtration rate Z-score (initiation: −4.51 ± 2.60; 3 yr: −0.93 ± 2.50) tended to be higher at 3 yr following burosumab treatment. Rickets Severity Score (initiation: 2.38 ± 1.44; 3 yr: 0.83 ± 0.53) and alkaline phosphatase Z-score (initiation: 3.11 ± 1.79; 3 yr: 1.71 ± 1.14) tended to be lower at 3 yr. The subgroup analyses by RSS also showed similar results. Height Z-score, phosphate Z-score, and 1,25(OH)2D tended to be higher at 3 yr in both subgroups, while alkaline phosphatase Z-score tended to be lower. In the subgroup analysis by alkaline phosphatase status, height Z-score tended to be higher at 3 yr only in the ≥upper limit of normal subgroup; the other results were comparable. Overall, height, phosphate homeostasis, and bone health may improve in children with XLH (including RSS <2) following burosumab treatment.

  • Open Access

    The Maintenance of Dysmyelinated Small‐Diameter Axons by 14‐3‐3s in the Central Nervous System

    by Nanako Yamada, Hinako Saito, Riko Takahashi, Mio Fujisato, Yukina Hosoda, Binri Sasaki, Momona Yamada, Sakurako Abe, Chikako Hayashi, Akira Yoshimoto, et al.

    In the central nervous system, myelin formed around nerve axons by oligodendrocyte enables efficient conduction of action potentials and maintains axonal homeostasis. Therefore, in demyelinating diseases, such as multiple sclerosis (MS), axonal degeneration and loss, particularly in small‐diameter axons, are observed. Teneurin‐4 deficient (Ten‐4 ‐/‐) mice exhibit severe dysmyelination of small‐diameter axons, but survive for over a year. Here, we aimed to elucidate the mechanism of the survival of small‐diameter axons without myelin using Ten‐4 ‐/‐ mice. An immunohistochemical analysis showed abnormally diffused and intense staining of neurofilament. Further, the immunohistochemical signal of nonphosphorylated neurofilament and amyloid precursor protein was higher in Ten‐4 ‐/‐ mice. An electron microscopy analysis unexpectedly revealed that small‐diameter axons in Ten‐4 ‐/‐ mice survived at the age of 1 year, despite the absence of compact myelin. To elucidate the molecular mechanism, we performed a proteomics analysis in the Ten‐4 ‐/‐ tissue by mass spectrometry. The result indicated that four of the seven 14‐3‐3 isoforms were highly expressed in Ten‐4 ‐/‐ small‐diameter axons. Finally, when the function of 14‐3‐3s in Ten‐4 ‐/‐ mice was inhibited by 14‐3‐3 inhibitors, BV02 and difopein, the progression of small‐diameter axon damage was observed. Altogether, 14‐3‐3s are among the pro‐survival factors in dysmyelinated small‐diameter axons. Our findings may be useful for better understanding the pathogenesis of demyelinating diseases, such as MS, as well as for the development of new treatments.